On this site you will find clinical studies with cannabis or single
cannabinoids in different diseases and case reports on the use of cannabis by
You may search for diseases (indications), authors, medication,
study design (controlled study, open trial, case report etc.) and other criteria.
|Title||A study of levonantradol, a cannabinol derivative, for analgesia in post operative pain.|
|Author(s)||Kantor TG, Hopper M.|
|Journal, Volume, Issue||Pain 1981; (suppl): S37.|
|Major outcome(s)||Levonantradol has analgetic activity but may have central nervous system adverse effects in humans.|
Aim of Investigation: Certain cannabinoids have been said to confer analgesia in humans. In animal studies, nantradol appeared to be potent but was a mixture of 2 sets of diastereoisomers. Individual dose ranging in humans isolated 1 of the 4 possible compounds as being most analgesic.
Methods: Double-blind studies of both parenteral and oral doses compared to placebo were then undertaken. 61 patients were treated in a single dose, random presentation, double-blind trial of a cannabinoid, Levonantradol, administered intramuscularly. 3 doses of the test drug, 0.25 mgm., 0.6 mgm. and 1.0 mgm., and placebo form the 4 cells of this study. Side effects noted were 2 instances of euphoria, 3 instances of drowsiness, 2 instances of dry mouth and 1 instance of nausea out of the 61 patients treated and all adverse effects were mild.
20 patients have received oral doses of this drug in doses ranging between 1.5 and 3.0 mgm. and show more analgesic effect on early breaking of the code. 1 patient had a 6 hour catatonic response which followed sudden cassation of propanolol and a 3 mgm. dose of Levonantradol. Another had paranoid ideation. This trial will continue until a total of 56 patients have been treated.
Results: In the intramuscular Levonantradol trial, SPID scores for the respective doses of drug noted above were 2.6, 3.0 and 4.3 for the 4 hour observation period. Placebo SPID score was 2.6
Conclusion: We conclude that nantradol has analgetic activity but may have central nervous system adverse effects in humans.
|Type of publication||Medical journal|
|Address of author(s)||Dept. of Medicine, New York University School of Medicine, New York, New York 10016.|